2024-11-05T00:26:17-06:00 2023-12-31 141442607 BST & CO CPAS LLP 10 BRITISH AMERICAN BLVD LATHAM NY 12110 990 2023-01-01 203654626 REGENERATIVE RESEARCH FOUNDATION REGE 5186948188 ONE DISCOVERY DRIVE RENSSELAER NY 12144 WILLIAM KAHN CPA CHAIR 5186948188 2024-11-04 1 1 JEREMY COLE P00436330 5184596700 2024-10-28 2023 2024-10-15 13:58:12Z NEURAL STEM CELL INSTITUTE WILLIAM KAHN CPA ONE DISCOVERY DRIVE RENSSELAER NY 12144 8795245 0 X WWW.NEURALSCI.ORG X 2005 NY THE PRINCIPAL MISSION OF THE REGENERATIVE RESEARCH FOUNDATION IS TO DEVELOP REGENERATIVE STEM CELL THERAPIES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS): THE BRAIN, SPINAL CORD, AND RETINA. 8 7 50 17 0 0 6469338 7786967 577571 700000 204 57424 485036 250854 7532149 8795245 0 0 0 0 2753191 2941974 0 0 0 3096056 4363132 5849247 7305106 1682902 1490139 5981949 6996425 1959438 1483775 4022511 5512650 X THE PRINCIPAL MISSION OF THE REGENERATIVE RESEARCH FOUNDATION IS TO DEVELOP REGENERATIVE STEM CELL THERAPIES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS): THE BRAIN, SPINAL CORD, AND RETINA. 0 0 3829833 450000 FISCAL YEAR 2023 WAS A PRODUCTIVE YEAR FOR THE REGENERATIVE RESEARCH FOUNDATION. RESEARCH ACTIVITY RETURNED TO PRE-PANDEMIC LEVELS. THE LABORATORIES WERE FULLY STAFFED AND PRODUCTIVE ALLOWING THE FOUNDATION TO PURSUE ITS MISSION TO EXPAND THE SCIENTIFIC KNOWLEDGE BASE AND DEVELOP POTENTIAL THERAPIES FOR TREATMENT FOR CENTRAL NERVOUS SYSTEM DISORDERS. FOUNDATION RESEARCHERS PUBLISHED A TOTAL OF NINE ARTICLES IN SEVERAL PROMINENT SCIENTIFIC JOURNALS REPORTING THE RESULTS OF THEIR INVESTIGATIONS. THE TOPICS INCLUDED NEURODEGENERATIVE DISEASE, EYE DISEASE AND SPINAL CORD INJURY. THESE ARTICLES ARE MADE AVAILABLE THROUGH THE NATIONAL INSTITUTES OF HEALTH PUB-MED CENTRAL PUBLICATION RETRIEVAL SYSTEM ALLOWING FREE ACCESS FOR THE SCIENTIFIC COMMUNITY AND THE PUBLIC. FOUNDATION INVESTIGATORS WERE ABLE TO SECURE 12 NEW RESEARCH GRANTS TO CONTINUE AND EXPAND THEIR RESEARCH PROGRAMS. 941803 250000 THE CLINICAL TRIAL CONTINUED TO PROGRESS DURING FISCAL YEAR 2023 OVERCOMING UNEXPECTED DELAYS. THE STUDY CONTINUES TO RECRUIT NEW SUBJECTS AND COLLECTED POST-SURGERY DATA FOR SUBJECTS AT THE ONE-YEAR MARK. THE FOUNDATION HOPES TO EXPAND THE CLINICAL STUDY BY DEVELOPING PARTNERSHIPS WITH OTHER CLINICAL RESEARCH SITES WHICH WILL EXPAND THE SUBJECT RECRUITMENT POPULATION AND POTENTIALLY ACCELERATE FDA APPROVAL FOR TREATMENT OF AMD. THE FOUNDATION'S INVESTIGATORS PRESENTED THE RESULTS OF THEIR EYE RESEARCH AS INVITED GUEST SPEAKERS AT ACADEMIC INSTITUTIONS AND AT SCIENTIFIC CONFERENCES. 1414282 THE ALZHEIMER'S AND RELATED DEMENTIA RESEARCH PROGRAM CONTINUED ITS INVESTIGATIONS INTO THE CAUSES AND POTENTIAL TREATMENTS FOR THESE DISEASES. THE CONSORTIUM OF ORGANIZATIONS AND INVESTIGATORS OF WHICH THE FOUNDATION IS THE LEAD ORGANIZATION CONTINUED TO PURSUE ITS RESEARCH AIMS FOCUSED ON IDENTIFYING GENES ASSOCIATED WITH THE DEVELOPMENT OF DEMENTIA. THE NATIONAL INSTITUTES OF HEALTH AND SEVERAL PUBLIC CHARITIES CONTINUE TO SUPPORT THIS PROGRAM STRATEGICALLY AND FINANCIALLY. THE FOUNDATION CONTINUED ITS PARTNERSHIP WITH A BIOTECHNOLOGY COMPANY TO RESEARCH AND DEVELOP A PROMISING NEURODEGENERATIVE DISEASE TREATMENT. 6185918 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 1 50 1 0 0 0 0 0 0 0 0 0 0 0 0 X 8 7 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY X THOMAS J IRWIN 5186948189 ONE DISCOVERY DRIVE RENSSELAER NY 12144 WILLIAM KAHN CPA CHAIR 5.00 X X 0 0 0 JEFFREY H STERN MD PHD DIRECTOR FOR TRANSLATIONAL 30.00 X X 51727 0 685 JOHN WALSH DIRECTOR 2.00 X 0 0 0 VITO GRASSO MPA CAE DIRECTOR 1.00 X 0 0 0 DAVID O CARPENTER MD DIRECTOR 1.00 X 0 0 0 DAWN ABBUHL DIRECTOR 1.00 X 0 0 0 ROBERT CATALANO MD DIRECTOR 1.00 X 0 0 0 AMY G KLANN PHD JD DIRECTOR 1.00 X 0 0 0 SALLY TEMPLE-STERN PHD SCIENTIFIC & EXECUTIVE DIR 65.00 X 177305 0 14115 CAITLIN HILL PRINCIPAL INVESTIGATOR 50.00 X 131209 0 7025 THOMAS KIEHL PRINCIPAL INVESTIGATOR 50.00 X 116681 0 13916 476922 0 35741 3 0 1 0 0 6533713 1253254 7786967 SPONSORED RESEARCH 541700 700000 700000 700000 57424 57424 26305 26305 NEURACELL INCOME 541700 205732 205732 OTHER 541700 18817 18817 224549 8795245 700000 0 308278 243832 234261 9571 2223103 1760385 462718 69529 50563 18966 220557 163399 57158 184953 138346 46607 146641 146641 32621 32621 364663 155426 209237 32278 15959 16319 35836 6991 28845 396084 384268 11816 81373 54435 26938 18929 9252 9677 34 34 65283 65283 32106 32106 RESEARCH SUBCONTRACTS 1796215 1796215 LABORATORY CHARGES 1198347 1071704 126643 EQUIP. REPAIR & MAINT. 125466 125421 45 MISCELLANEOUS 37256 7369 29887 7305106 6185918 1119188 0 678162 433733 1931726 3639688 1693916 1809146 203006 206672 120161 157309 4168867 3681890 93001 486977 1261977 262900 5981949 6996425 711170 1221043 1248268 262732 1959438 1483775 X 3024854 4252040 997657 1260610 4022511 5512650 5981949 6996425 1490139 0 X 0 1 X 1 1 1 X 3109318 2767480 4650213 6469338 7786968 24783317 3109318 2767480 4650213 6469338 7786968 24783317 2026099 22757218 26048 12077 7275 27808 83729 156937 112749 99146 160911 457432 224548 1054786 25995040 2537665 0.87540 0.83970 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2020 AMOUNT: $ 4,335. 2023 AMOUNT: $ 18,816. NEURACELL INCOME - 2019 AMOUNT: $ 112,749. 2020 AMOUNT: $ 94,811. 2021 AMOUNT: $ 160,911. 2022 AMOUNT: $ 457,432. 2023 AMOUNT: $ 205,732. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 24699 23892 807 4144168 3657998 486170 486977 OPERATING LEASE LIABILITY 262732 262732 X 8795245 0 8795245 0 8795245 7305106 0 7305106 0 7305106 PART X, LINE 2: THE FOUNDATION FILES FORM 990 ANNUALLY WITH THE INTERNAL REVENUE SERVICE. WHEN ANNUAL RETURNS ARE FILED, SOME TAX POSITIONS TAKEN ARE HIGHLY CERTAIN TO BE SUSTAINED UPON EXAMINATION BY THE TAXING AUTHORITIES, WHILE OTHER TAX POSITIONS ARE SUBJECT TO UNCERTAINTY ABOUT THE TECHNICAL MERITS OF THE POSITION OR AMOUNT OF THE POSITION'S TAX BENEFIT THAT WOULD ULTIMATELY BE SUSTAINED. MANAGEMENT EVALUATED THE FOUNDATION'S TAX POSITIONS, INCLUDING INTEREST AND PENALTIES ATTRIBUTABLE THERETO, AND CONCLUDED THAT THE FOUNDATION HAD TAKEN NO TAX POSITION THAT REQUIRED ADJUSTMENT IN ITS FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 OR 2022. X X 0 0 0 0 0 0 0 0 0 SALLY TEMPLE-STERN PHD SCIENTIFIC & EXECUTIVE DIR 177305 0 0 0 0 0 7154 0 6961 0 191420 0 0 0 SALLY TEMPLE-STERN SEE PART V 191420 SEE PART V 0 JEFFREY H STERN SEE PART V 52412 SEE PART V 0 SCHEDULE L, PART IV, LINE 1, COLUMN B: SALLY TEMPLE-STERN IS THE EXECUTIVE AND SCIENTIFIC DIRECTOR OF THE ORGANIZATION AND ALSO HAS A FAMILY RELATIONSHIP WITH A CURRENT BOARD MEMBER. SCHEDULE L, PART IV, LINE 1, COLUMN D: SALLY TEMPLE-STERN IS COMPENSATED FOR SERVICES PERFORMED AS THE EXECUTIVE AND SCIENTIFIC DIRECTOR OF THE ORGANIZATION. HER COMPENSATION IS DETERMINED BY THE GOVERNING BOARD AS DISCLOSED IN SCHEDULE O. SCHEDULE L, PART IV, LINE 2, COLUMN B: JEFFREY H. STERN IS THE TRANSLATIONAL RESEARCH DIRECTOR OF THE ORGANIZATION AND ALSO HAS A FAMILY RELATIONSHIP WITH A CURRENT OFFICER. SCHEDULE L, PART IV, LINE 2, COLUMN D: JEFFREY H. STERN IS COMPENSATED FOR SERVICES PERFORMED AS THE TRANSLATIONAL RESEARCH DIRECTOR OF THE ORGANIZATION. HIS COMPENSATION IS DETERMINED BY THE GOVERNING BOARD AS DISCLOSED IN SCHEDULE O. FORM 990, PART VI, SECTION A, LINE 2 DR. JEFFREY STERN AND DR. SALLY TEMPLE-STERN HAVE A FAMILY AND BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE ORGANIZATION'S FORM 990 WAS DISTRIBUTED TO AND REVIEWED BY THE BOARD PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C EVERY BOARD MEMBER IS PROVIDED A COPY OF THE CONFLICT OF INTEREST POLICY AND ALL RELATIONSHIPS INVOLVING AN APPARENT OR POTENTIAL CONFLICT OF INTEREST ARE DISCUSSED BY THE BOARD IN ADVANCE OF THE FOUNDATION ENTERING INTO ANY TRANSACTION OR RELATIONSHIP. THE BOARD ALSO REVIEWS ITS CONFLICT OF INTEREST POLICY ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION OF ALL EMPLOYEES INCLUDING THE FOUNDATION'S EXECUTIVE DIRECTOR AND OTHER INDIVIDUALS IS REVIEWED AND APPROVED PERIODICALLY BY THE GOVERNING BOARD. THE BOARD CONSIDERS BOTH COMPARATIVE POSITIONS AND GEOGRAPHIC FACTORS WHEN MAKING ITS DECISION. FORM 990, PART VI, SECTION C, LINE 19 ALL FOUNDATION GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST EITHER IN PERSON, BY TELEPHONE OR EMAIL.